The Absurd COVID-19 Vaccine Regulatory Race

Donald Trump is no longer the only one who thinks the US FDA is moving too slow on allowing broad access to COVID-19 vaccine candidates. But before the narrative that FDA’s caution cost lives takes root, let’s remember the facts: the key milestone isn’t when an effective vaccine is authorized, but when supplies are sufficient to mount an effective vaccination campaign.